Targeting triple negative breast cancer heterogeneity with chalcones: a molecular insight
Triple negative breast cancers (TNBCs) are aggressive heterogeneous cancers with not yet determined conventional targeted medication. Therefore, identification of new alternatives or improved treatment options to combat this deadly disease is highly needed. On the other hand, various derived products with chalcone scaffold were historically considered excellent candidates for the development of anticancer drugs. Chalcones unique chemical structure and their substantial biological activities in cancer cells make them an extremely attractive target for the treatment of several human carcinomas including TNBCs. This review highlights the promising therapeutic role of chalcones in TNBC management.
Other Information
Published in: Journal of Drug Targeting
License: http://creativecommons.org/licenses/by-nc-nd/4.0/
See article on publisher's website: https://dx.doi.org/10.1080/1061186x.2018.1561889
Funding
Open Access funding provided by the Qatar National Library.
History
Language
- English
Publisher
Taylor & FrancisPublication Year
- 2019
License statement
This Item is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.Institution affiliated with
- Qatar University
- Biomedical Research Center - QU
- Qatar University Health - QU
- College of Pharmacy - QU HEALTH
- College of Medicine - QU HEALTH